Progress on the Study of Targeting FGFR in Squamous Non-small Cell Lung Cancer.
10.3779/j.issn.1009-3419.2018.02.05
- Author:
Ming DONG
1
;
Tong LI
1
;
Jun CHEN
1
Author Information
1. Department of Lung Cancer Surgery, Tianjin Medical University General Hospital, Tianjin 300052, China.
- Publication Type:Journal Article
- Keywords:
FGFR;
SqCLC;
Targeting
- MeSH:
Carcinoma, Non-Small-Cell Lung;
drug therapy;
genetics;
metabolism;
Carcinoma, Squamous Cell;
drug therapy;
genetics;
metabolism;
Humans;
Lung Neoplasms;
drug therapy;
genetics;
metabolism;
Molecular Targeted Therapy;
methods;
Mutation;
Receptors, Fibroblast Growth Factor;
genetics;
metabolism
- From:
Chinese Journal of Lung Cancer
2018;21(2):116-120
- CountryChina
- Language:Chinese
-
Abstract:
Squamous cell lung cancer (SqCLC) is a unique clinical and histologic category of non-small cell lung cancer (NSCLC). Most of patients with SqCLC tend to be older, typically at advanced stage, associated with smoking and have more complications. With progress of targeted therapy of lung cancer, we identified several potential actionable genetic abnormalities such as FGFR. Several FGFR inhibitors have been approved for clinical use in different cancers. And some of these agents are currently under investigation in clinical trials for SqCLC. This article summarizes the current knowledge about FGFR aberrations, the relative inhibitors in development and clinical data in SqCLC.
